Industry Research Reports

Home > Reports > Pharma & Healthcare > AT1 Receptor Antagonists - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

AT1 Receptor Antagonists - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-24

Pages: 134 Pages

Report ld: 2332020

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

AT1 receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.

The global market for AT1 Receptor Antagonists was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for AT1 Receptor Antagonists was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for AT1 Receptor Antagonists was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for AT1 Receptor Antagonists was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of AT1 Receptor Antagonists include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for AT1 Receptor Antagonists, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of AT1 Receptor Antagonists by region & country, by Type, and by Application.

The AT1 Receptor Antagonists market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AT1 Receptor Antagonists.

Market Segmentation

Report Metric
Details
Report Title
AT1 Receptor Antagonists - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global AT1 Receptor Antagonists Companies Covered
Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical
Global AT1 Receptor Antagonists Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global AT1 Receptor Antagonists Market, Segment by Type
Valsartan

Telmisartan

Losartan

Irbesartan

Azilsartan

Olmesartan
Global AT1 Receptor Antagonists Market, Segment by Application
Hypertension

Cardiovascular Diseases

Kidney Diseases

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of AT1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of AT1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of AT1 Receptor Antagonists in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 AT1 Receptor Antagonists Product Introduction
    1.2 Global AT1 Receptor Antagonists Market Size Forecast
        1.2.1 Global AT1 Receptor Antagonists Sales Value (2019-2030)
        1.2.2 Global AT1 Receptor Antagonists Sales Volume (2019-2030)
        1.2.3 Global AT1 Receptor Antagonists Sales Price (2019-2030)
    1.3 AT1 Receptor Antagonists Market Trends & Drivers
        1.3.1 AT1 Receptor Antagonists Industry Trends
        1.3.2 AT1 Receptor Antagonists Market Drivers & Opportunity
        1.3.3 AT1 Receptor Antagonists Market Challenges
        1.3.4 AT1 Receptor Antagonists Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global AT1 Receptor Antagonists Players Revenue Ranking (2023)
    2.2 Global AT1 Receptor Antagonists Revenue by Company (2019-2024)
    2.3 Global AT1 Receptor Antagonists Players Sales Volume Ranking (2023)
    2.4 Global AT1 Receptor Antagonists Sales Volume by Company Players (2019-2024)
    2.5 Global AT1 Receptor Antagonists Average Price by Company (2019-2024)
    2.6 Key Manufacturers AT1 Receptor Antagonists Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers AT1 Receptor Antagonists Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of AT1 Receptor Antagonists
    2.9 AT1 Receptor Antagonists Market Competitive Analysis
        2.9.1 AT1 Receptor Antagonists Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by AT1 Receptor Antagonists Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AT1 Receptor Antagonists as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Valsartan
        3.1.2 Telmisartan
        3.1.3 Losartan
        3.1.4 Irbesartan
        3.1.5 Azilsartan
        3.1.6 Olmesartan
    3.2 Global AT1 Receptor Antagonists Sales Value by Type
        3.2.1 Global AT1 Receptor Antagonists Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global AT1 Receptor Antagonists Sales Value, by Type (2019-2030)
        3.2.3 Global AT1 Receptor Antagonists Sales Value, by Type (%) (2019-2030)
    3.3 Global AT1 Receptor Antagonists Sales Volume by Type
        3.3.1 Global AT1 Receptor Antagonists Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global AT1 Receptor Antagonists Sales Volume, by Type (2019-2030)
        3.3.3 Global AT1 Receptor Antagonists Sales Volume, by Type (%) (2019-2030)
    3.4 Global AT1 Receptor Antagonists Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hypertension
        4.1.2 Cardiovascular Diseases
        4.1.3 Kidney Diseases
        4.1.4 Other
    4.2 Global AT1 Receptor Antagonists Sales Value by Application
        4.2.1 Global AT1 Receptor Antagonists Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global AT1 Receptor Antagonists Sales Value, by Application (2019-2030)
        4.2.3 Global AT1 Receptor Antagonists Sales Value, by Application (%) (2019-2030)
    4.3 Global AT1 Receptor Antagonists Sales Volume by Application
        4.3.1 Global AT1 Receptor Antagonists Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global AT1 Receptor Antagonists Sales Volume, by Application (2019-2030)
        4.3.3 Global AT1 Receptor Antagonists Sales Volume, by Application (%) (2019-2030)
    4.4 Global AT1 Receptor Antagonists Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global AT1 Receptor Antagonists Sales Value by Region
        5.1.1 Global AT1 Receptor Antagonists Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global AT1 Receptor Antagonists Sales Value by Region (2019-2024)
        5.1.3 Global AT1 Receptor Antagonists Sales Value by Region (2025-2030)
        5.1.4 Global AT1 Receptor Antagonists Sales Value by Region (%), (2019-2030)
    5.2 Global AT1 Receptor Antagonists Sales Volume by Region
        5.2.1 Global AT1 Receptor Antagonists Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global AT1 Receptor Antagonists Sales Volume by Region (2019-2024)
        5.2.3 Global AT1 Receptor Antagonists Sales Volume by Region (2025-2030)
        5.2.4 Global AT1 Receptor Antagonists Sales Volume by Region (%), (2019-2030)
    5.3 Global AT1 Receptor Antagonists Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America AT1 Receptor Antagonists Sales Value, 2019-2030
        5.4.2 North America AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe AT1 Receptor Antagonists Sales Value, 2019-2030
        5.5.2 Europe AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific AT1 Receptor Antagonists Sales Value, 2019-2030
        5.6.2 Asia Pacific AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America AT1 Receptor Antagonists Sales Value, 2019-2030
        5.7.2 South America AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa AT1 Receptor Antagonists Sales Value, 2019-2030
        5.8.2 Middle East & Africa AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions AT1 Receptor Antagonists Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions AT1 Receptor Antagonists Sales Value
        6.2.1 Key Countries/Regions AT1 Receptor Antagonists Sales Value, 2019-2030
        6.2.2 Key Countries/Regions AT1 Receptor Antagonists Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States AT1 Receptor Antagonists Sales Value, 2019-2030
        6.3.2 United States AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe AT1 Receptor Antagonists Sales Value, 2019-2030
        6.4.2 Europe AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China AT1 Receptor Antagonists Sales Value, 2019-2030
        6.5.2 China AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.5.3 China AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan AT1 Receptor Antagonists Sales Value, 2019-2030
        6.6.2 Japan AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea AT1 Receptor Antagonists Sales Value, 2019-2030
        6.7.2 South Korea AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia AT1 Receptor Antagonists Sales Value, 2019-2030
        6.8.2 Southeast Asia AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India AT1 Receptor Antagonists Sales Value, 2019-2030
        6.9.2 India AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
        6.9.3 India AT1 Receptor Antagonists Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Company Information
        7.1.2 Pfizer Introduction and Business Overview
        7.1.3 Pfizer AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Pfizer AT1 Receptor Antagonists Product Offerings
        7.1.5 Pfizer Recent Development
    7.2 Novartis
        7.2.1 Novartis Company Information
        7.2.2 Novartis Introduction and Business Overview
        7.2.3 Novartis AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Novartis AT1 Receptor Antagonists Product Offerings
        7.2.5 Novartis Recent Development
    7.3 Merck
        7.3.1 Merck Company Information
        7.3.2 Merck Introduction and Business Overview
        7.3.3 Merck AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Merck AT1 Receptor Antagonists Product Offerings
        7.3.5 Merck Recent Development
    7.4 Astra Zeneca
        7.4.1 Astra Zeneca Company Information
        7.4.2 Astra Zeneca Introduction and Business Overview
        7.4.3 Astra Zeneca AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Astra Zeneca AT1 Receptor Antagonists Product Offerings
        7.4.5 Astra Zeneca Recent Development
    7.5 Jhonson and Johnson
        7.5.1 Jhonson and Johnson Company Information
        7.5.2 Jhonson and Johnson Introduction and Business Overview
        7.5.3 Jhonson and Johnson AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Jhonson and Johnson AT1 Receptor Antagonists Product Offerings
        7.5.5 Jhonson and Johnson Recent Development
    7.6 Eli Lilly
        7.6.1 Eli Lilly Company Information
        7.6.2 Eli Lilly Introduction and Business Overview
        7.6.3 Eli Lilly AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Eli Lilly AT1 Receptor Antagonists Product Offerings
        7.6.5 Eli Lilly Recent Development
    7.7 Sanofi
        7.7.1 Sanofi Company Information
        7.7.2 Sanofi Introduction and Business Overview
        7.7.3 Sanofi AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Sanofi AT1 Receptor Antagonists Product Offerings
        7.7.5 Sanofi Recent Development
    7.8 Bristol-Myers Squibb
        7.8.1 Bristol-Myers Squibb Company Information
        7.8.2 Bristol-Myers Squibb Introduction and Business Overview
        7.8.3 Bristol-Myers Squibb AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 Bristol-Myers Squibb AT1 Receptor Antagonists Product Offerings
        7.8.5 Bristol-Myers Squibb Recent Development
    7.9 Bayer
        7.9.1 Bayer Company Information
        7.9.2 Bayer Introduction and Business Overview
        7.9.3 Bayer AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Bayer AT1 Receptor Antagonists Product Offerings
        7.9.5 Bayer Recent Development
    7.10 GSK
        7.10.1 GSK Company Information
        7.10.2 GSK Introduction and Business Overview
        7.10.3 GSK AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 GSK AT1 Receptor Antagonists Product Offerings
        7.10.5 GSK Recent Development
    7.11 Teva Pharmaceutical
        7.11.1 Teva Pharmaceutical Company Information
        7.11.2 Teva Pharmaceutical Introduction and Business Overview
        7.11.3 Teva Pharmaceutical AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
        7.11.4 Teva Pharmaceutical AT1 Receptor Antagonists Product Offerings
        7.11.5 Teva Pharmaceutical Recent Development

 8 Industry Chain Analysis
    8.1 AT1 Receptor Antagonists Industrial Chain
    8.2 AT1 Receptor Antagonists Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 AT1 Receptor Antagonists Sales Model
        8.5.2 Sales Channel
        8.5.3 AT1 Receptor Antagonists Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. AT1 Receptor Antagonists Market Trends
    Table 2. AT1 Receptor Antagonists Market Drivers & Opportunity
    Table 3. AT1 Receptor Antagonists Market Challenges
    Table 4. AT1 Receptor Antagonists Market Restraints
    Table 5. Global AT1 Receptor Antagonists Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global AT1 Receptor Antagonists Revenue Market Share by Company (2019-2024)
    Table 7. Global AT1 Receptor Antagonists Sales Volume by Company (2019-2024) & (K MT)
    Table 8. Global AT1 Receptor Antagonists Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market AT1 Receptor Antagonists Price by Company (2019-2024) & (USD/MT)
    Table 10. Key Manufacturers AT1 Receptor Antagonists Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers AT1 Receptor Antagonists Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of AT1 Receptor Antagonists
    Table 13. Global AT1 Receptor Antagonists Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AT1 Receptor Antagonists as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global AT1 Receptor Antagonists Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global AT1 Receptor Antagonists Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global AT1 Receptor Antagonists Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global AT1 Receptor Antagonists Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global AT1 Receptor Antagonists Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global AT1 Receptor Antagonists Sales Volume by Type: 2019 VS 2023 VS 2030 (K MT)
    Table 22. Global AT1 Receptor Antagonists Sales Volume by Type (2019-2024) & (K MT)
    Table 23. Global AT1 Receptor Antagonists Sales Volume by Type (2025-2030) & (K MT)
    Table 24. Global AT1 Receptor Antagonists Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global AT1 Receptor Antagonists Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global AT1 Receptor Antagonists Price by Type (2019-2024) & (USD/MT)
    Table 27. Global AT1 Receptor Antagonists Price by Type (2025-2030) & (USD/MT)
    Table 28. Global AT1 Receptor Antagonists Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global AT1 Receptor Antagonists Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global AT1 Receptor Antagonists Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global AT1 Receptor Antagonists Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global AT1 Receptor Antagonists Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global AT1 Receptor Antagonists Sales Volume by Application: 2019 VS 2023 VS 2030 (K MT)
    Table 34. Global AT1 Receptor Antagonists Sales Volume by Application (2019-2024) & (K MT)
    Table 35. Global AT1 Receptor Antagonists Sales Volume by Application (2025-2030) & (K MT)
    Table 36. Global AT1 Receptor Antagonists Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global AT1 Receptor Antagonists Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global AT1 Receptor Antagonists Price by Application (2019-2024) & (USD/MT)
    Table 39. Global AT1 Receptor Antagonists Price by Application (2025-2030) & (USD/MT)
    Table 40. Global AT1 Receptor Antagonists Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global AT1 Receptor Antagonists Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global AT1 Receptor Antagonists Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global AT1 Receptor Antagonists Sales Value by Region (2019-2024) & (%)
    Table 44. Global AT1 Receptor Antagonists Sales Value by Region (2025-2030) & (%)
    Table 45. Global AT1 Receptor Antagonists Sales Volume by Region (K MT): 2019 VS 2023 VS 2030
    Table 46. Global AT1 Receptor Antagonists Sales Volume by Region (2019-2024) & (K MT)
    Table 47. Global AT1 Receptor Antagonists Sales Volume by Region (2025-2030) & (K MT)
    Table 48. Global AT1 Receptor Antagonists Sales Volume by Region (2019-2024) & (%)
    Table 49. Global AT1 Receptor Antagonists Sales Volume by Region (2025-2030) & (%)
    Table 50. Global AT1 Receptor Antagonists Average Price by Region (2019-2024) & (USD/MT)
    Table 51. Global AT1 Receptor Antagonists Average Price by Region (2025-2030) & (USD/MT)
    Table 52. Key Countries/Regions AT1 Receptor Antagonists Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions AT1 Receptor Antagonists Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions AT1 Receptor Antagonists Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions AT1 Receptor Antagonists Sales Volume, (2019-2024) & (K MT)
    Table 56. Key Countries/Regions AT1 Receptor Antagonists Sales Volume, (2025-2030) & (K MT)
    Table 57. Pfizer Company Information
    Table 58. Pfizer Introduction and Business Overview
    Table 59. Pfizer AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 60. Pfizer AT1 Receptor Antagonists Product Offerings
    Table 61. Pfizer Recent Development
    Table 62. Novartis Company Information
    Table 63. Novartis Introduction and Business Overview
    Table 64. Novartis AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 65. Novartis AT1 Receptor Antagonists Product Offerings
    Table 66. Novartis Recent Development
    Table 67. Merck Company Information
    Table 68. Merck Introduction and Business Overview
    Table 69. Merck AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 70. Merck AT1 Receptor Antagonists Product Offerings
    Table 71. Merck Recent Development
    Table 72. Astra Zeneca Company Information
    Table 73. Astra Zeneca Introduction and Business Overview
    Table 74. Astra Zeneca AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 75. Astra Zeneca AT1 Receptor Antagonists Product Offerings
    Table 76. Astra Zeneca Recent Development
    Table 77. Jhonson and Johnson Company Information
    Table 78. Jhonson and Johnson Introduction and Business Overview
    Table 79. Jhonson and Johnson AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 80. Jhonson and Johnson AT1 Receptor Antagonists Product Offerings
    Table 81. Jhonson and Johnson Recent Development
    Table 82. Eli Lilly Company Information
    Table 83. Eli Lilly Introduction and Business Overview
    Table 84. Eli Lilly AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 85. Eli Lilly AT1 Receptor Antagonists Product Offerings
    Table 86. Eli Lilly Recent Development
    Table 87. Sanofi Company Information
    Table 88. Sanofi Introduction and Business Overview
    Table 89. Sanofi AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 90. Sanofi AT1 Receptor Antagonists Product Offerings
    Table 91. Sanofi Recent Development
    Table 92. Bristol-Myers Squibb Company Information
    Table 93. Bristol-Myers Squibb Introduction and Business Overview
    Table 94. Bristol-Myers Squibb AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 95. Bristol-Myers Squibb AT1 Receptor Antagonists Product Offerings
    Table 96. Bristol-Myers Squibb Recent Development
    Table 97. Bayer Company Information
    Table 98. Bayer Introduction and Business Overview
    Table 99. Bayer AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 100. Bayer AT1 Receptor Antagonists Product Offerings
    Table 101. Bayer Recent Development
    Table 102. GSK Company Information
    Table 103. GSK Introduction and Business Overview
    Table 104. GSK AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 105. GSK AT1 Receptor Antagonists Product Offerings
    Table 106. GSK Recent Development
    Table 107. Teva Pharmaceutical Company Information
    Table 108. Teva Pharmaceutical Introduction and Business Overview
    Table 109. Teva Pharmaceutical AT1 Receptor Antagonists Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 110. Teva Pharmaceutical AT1 Receptor Antagonists Product Offerings
    Table 111. Teva Pharmaceutical Recent Development
    Table 112. Key Raw Materials Lists
    Table 113. Raw Materials Key Suppliers Lists
    Table 114. AT1 Receptor Antagonists Downstream Customers
    Table 115. AT1 Receptor Antagonists Distributors List
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. AT1 Receptor Antagonists Product Picture
    Figure 2. Global AT1 Receptor Antagonists Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global AT1 Receptor Antagonists Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global AT1 Receptor Antagonists Sales Volume (2019-2030) & (K MT)
    Figure 5. Global AT1 Receptor Antagonists Sales Price (2019-2030) & (USD/MT)
    Figure 6. AT1 Receptor Antagonists Report Years Considered
    Figure 7. Global AT1 Receptor Antagonists Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global AT1 Receptor Antagonists Players Sales Volume Ranking (2023) & (K MT)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by AT1 Receptor Antagonists Revenue in 2023
    Figure 10. AT1 Receptor Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Valsartan Picture
    Figure 12. Telmisartan Picture
    Figure 13. Losartan Picture
    Figure 14. Irbesartan Picture
    Figure 15. Azilsartan Picture
    Figure 16. Olmesartan Picture
    Figure 17. Global AT1 Receptor Antagonists Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global AT1 Receptor Antagonists Sales Value Market Share by Type, 2023 & 2030
    Figure 19. Global AT1 Receptor Antagonists Sales Volume by Type (2019 VS 2023 VS 2030) & (K MT)
    Figure 20. Global AT1 Receptor Antagonists Sales Volume Market Share by Type, 2023 & 2030
    Figure 21. Global AT1 Receptor Antagonists Price by Type (2019-2030) & (USD/MT)
    Figure 22. Product Picture of Hypertension
    Figure 23. Product Picture of Cardiovascular Diseases
    Figure 24. Product Picture of Kidney Diseases
    Figure 25. Product Picture of Other
    Figure 26. Global AT1 Receptor Antagonists Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 27. Global AT1 Receptor Antagonists Sales Value Market Share by Application, 2023 & 2030
    Figure 28. Global AT1 Receptor Antagonists Sales Volume by Application (2019 VS 2023 VS 2030) & (K MT)
    Figure 29. Global AT1 Receptor Antagonists Sales Volume Market Share by Application, 2023 & 2030
    Figure 30. Global AT1 Receptor Antagonists Price by Application (2019-2030) & (USD/MT)
    Figure 31. North America AT1 Receptor Antagonists Sales Value (2019-2030) & (US$ Million)
    Figure 32. North America AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    Figure 33. Europe AT1 Receptor Antagonists Sales Value (2019-2030) & (US$ Million)
    Figure 34. Europe AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    Figure 35. Asia Pacific AT1 Receptor Antagonists Sales Value (2019-2030) & (US$ Million)
    Figure 36. Asia Pacific AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    Figure 37. South America AT1 Receptor Antagonists Sales Value (2019-2030) & (US$ Million)
    Figure 38. South America AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    Figure 39. Middle East & Africa AT1 Receptor Antagonists Sales Value (2019-2030) & (US$ Million)
    Figure 40. Middle East & Africa AT1 Receptor Antagonists Sales Value by Country (%), 2023 VS 2030
    Figure 41. Key Countries/Regions AT1 Receptor Antagonists Sales Value (%), (2019-2030)
    Figure 42. Key Countries/Regions AT1 Receptor Antagonists Sales Volume (%), (2019-2030)
    Figure 43. United States AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 44. United States AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 45. United States AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 46. Europe AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Europe AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 48. Europe AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 49. China AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 50. China AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 51. China AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 52. Japan AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 53. Japan AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 54. Japan AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 55. South Korea AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 56. South Korea AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 57. South Korea AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 58. Southeast Asia AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 59. Southeast Asia AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 60. Southeast Asia AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 61. India AT1 Receptor Antagonists Sales Value, (2019-2030) & (US$ Million)
    Figure 62. India AT1 Receptor Antagonists Sales Value by Type (%), 2023 VS 2030
    Figure 63. India AT1 Receptor Antagonists Sales Value by Application (%), 2023 VS 2030
    Figure 64. AT1 Receptor Antagonists Industrial Chain
    Figure 65. AT1 Receptor Antagonists Manufacturing Cost Structure
    Figure 66. Channels of Distribution (Direct Sales, and Distribution)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed

AT1 receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.

The global market for AT1 Receptor Antagonists was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for AT1 Receptor Antagonists was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for AT1 Receptor Antagonists was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for AT1 Receptor Antagonists was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of AT1 Receptor Antagonists include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for AT1 Receptor Antagonists, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of AT1 Receptor Antagonists by region & country, by Type, and by Application.

The AT1 Receptor Antagonists market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AT1 Receptor Antagonists.

Market Segmentation

Industry: Pharma & Healthcare

Published: 2024-01-24

Pages: 134 Pages

Report ld: 2332020

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 3950.00

Multi Users License

USD 5925.00

Corporate Users License